Highbridge Capital Management LLC Gamida Cell Ltd. Transaction History

Highbridge Capital Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$1.73 - $4.29 $342,323 - $848,883	197,875 Added 19.79%	1,197,875 $2.12 Million
Q1 2022 May 11, 2022	BUY	$2.22 - $4.47 $449,452 - $904,978	202,456 Added 25.38%	1,000,000 $4.15 Million
Q4 2021 Feb 11, 2022	BUY	$2.2 - $4.46 $1.75 Million - $3.56 Million	797,544 New	797,544 $2.03 Million

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Highbridge Capital Management LLC with notifications on news.